[Hemodynamic effects of prostaglandin E1 in patients with congenital heart disease and pulmonary hypertension].
Investigations were performed to determine whether prostaglandin E1 (PGE1) would get a favorable change in pulmonary hymodynamics in patients with congenital heart disease and elevated pulmonary vascular resistance. Thirty-seven patients were studied. PGE1 was infused into the pulmonary artery with 100-200 ng/kg.min. PGE1 caused a significant decrease in pulmonary artery pressure and in pulmonary resistance in low-resistance group (TPRO < or = 600 kPa.s/L) (P < 0.05). But PGE1 resulted in systemic hypotention in high-resistance group for the same dose (TPRO > 600 kPa.s/L). This study shows that PGE1 is an effective vasodilator. The doses and the effects of PGE1 are dependent on the degree of pulmonary vascular disease.
Pan
S
S
Fu Wai Hospital, Cardiovascular Institute, CAMS, Beijing.
Xiao
M
M
Liu
Y
Y
D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D006345:Heart Septal Defects, Ventricular / Q000150:complications / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000503:physiopathology*; D007223:Infant; D008297:Male; D011651:Pulmonary Artery / Q000187:drug effects; D011817:Rabbits; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D000527:Alprostadil